0000899243-19-004627.txt : 20190225 0000899243-19-004627.hdr.sgml : 20190225 20190225082939 ACCESSION NUMBER: 0000899243-19-004627 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190212 FILED AS OF DATE: 20190225 DATE AS OF CHANGE: 20190225 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McIntyre Gail Frances CENTRAL INDEX KEY: 0001492646 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36361 FILM NUMBER: 19628138 MAIL ADDRESS: STREET 1: C/O FURIEX PHARMACEUTICALS, INC. STREET 2: 3900 PARAMOUNT PARKWAY, SUITE 150 CITY: MORRISVILLE STATE: NC ZIP: 27560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aravive, Inc. CENTRAL INDEX KEY: 0001513818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264106690 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: LYONDELLBASELL TOWER STREET 2: 1221 MCKINNEY STREET, SUITE 3200 CITY: HOUSTON STATE: TX ZIP: 77010 BUSINESS PHONE: 936-355-1910 MAIL ADDRESS: STREET 1: LYONDELLBASELL TOWER STREET 2: 1221 MCKINNEY STREET, SUITE 3200 CITY: HOUSTON STATE: TX ZIP: 77010 FORMER COMPANY: FORMER CONFORMED NAME: Versartis, Inc. DATE OF NAME CHANGE: 20110223 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2019-02-12 0 0001513818 Aravive, Inc. ARAV 0001492646 McIntyre Gail Frances C/O ARAVIVE, INC., LYONDELLBASSELL TOWER 1221 MCKINNEY ST., STE 3200 HOUSTON TX 77010 0 1 0 0 Chief Scientific Officer Stock Option 0.66 2027-06-14 Common Stock 29641 D Stock Option 0.90 2027-12-13 Common Stock 14820 D Stock Option 0.90 2028-03-19 Common Stock 14820 D Shares of common stock of the corporation known as Aravive Biologics, Inc. ("Aravive Biologics") were converted into shares of Aravive, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018, by and among the Issuer (then under the name Versartis, Inc.), Velo Merger Sub, Inc. and Aravive Biologics (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement for the merger (the "Merger"), each share of Aravive Biologics common stock was exchanged for 2.2801 shares of the Issuer's common stock, subject to adjustment for any reverse stock split. Following the Merger, the Issuer effected a reverse stock split at a ratio of one new share for every six shares of Issuer common stock outstanding and the Issuer changed its name to Aravive, Inc. All share and option numbers reflect the reverse stock split. On June 15, 2017, the reporting person was granted an option to purchase 78,000 shares of common stock of Aravive Biologics at an exercise price of $0.23 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 29,641 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.66 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the Merger. December 14, 2017, the reporting person was granted an option to purchase 39,000 shares of common stock of Aravive Biologics at an exercise price of $0.34 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 14,820 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.90 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the Merger. On March 20, 2018, the reporting person was granted an option to purchase 39,000 shares of common stock of Aravive Biologics at an exercise price of $0.34 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 14,820 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.90 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the Merger. /s/ Gail F. McIntyre 2019-02-25